PRESS RELEASE published on 08/28/2023 at 13:30, 2 years 8 months ago NLS Pharmaceutics CEO Issues Letter to Shareholders
PRESS RELEASE published on 05/02/2023 at 14:45, 3 years ago NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
PRESS RELEASE published on 03/27/2023 at 14:30, 3 years 1 month ago NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
PRESS RELEASE published on 01/23/2023 at 14:30, 3 years 3 months ago NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
PRESS RELEASE published on 01/12/2023 at 14:30, 3 years 4 months ago NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Published on 05/23/2026 at 03:15, 9 hours 10 minutes ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 9 hours 25 minutes ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 10 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 10 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 01:00, 11 hours 25 minutes ago LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Development with Neuland Laboratories
Published on 05/22/2026 at 22:05, 14 hours 20 minutes ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 16 hours 33 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 18:33, 17 hours 52 minutes ago Update on Coupon payment due on 23 May 2026 and Preparation of the Green Bond Restructuring
Published on 05/22/2026 at 18:30, 17 hours 54 minutes ago Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Published on 05/22/2026 at 18:05, 18 hours 19 minutes ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 23 hours 32 minutes ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
Published on 05/22/2026 at 08:30, 1 day 3 hours ago Eiffage is building four solar power plants for the NOOR Atlas programme in Morocco
Published on 05/21/2026 at 17:45, 1 day 18 hours ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
